AMLX

#1890
Amylyx Pharmaceuticals, Inc. Common Stock
15.17
+1.68%
Secteur:
Base:
Devise de Profit:
Range quotidien
15.17
15.17
Range Annuel
2.60
17.49
Changement quotidien
+1.68%
Changement Mensuel
-2.00%
Evolution sur 6 mois
+60.53%
Changement Annuel
+384.66%
Clôture Précédente
14.92
Open
15.17
Bid
Ask
Low
15.17
High
15.17
Volume
174
Open full chart

Financials

Overview Relevé Statistics Dividends
Quarterly Annual
Income statement Balance sheet Cash flow
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25 TTM

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.

Nouvelles